Warning Letter — Ket Plug / ketaminelab.org and buyketaminepowderonline.com
The FDA Center for Drug Evaluation and Research issued a warning letter to Ket Plug for operating websites (ketaminelab.org and buyketaminepowderonline.com) that facilitate the distribution of products in violation of the Federal Food, Drug, and Cosmetic Act.
This affects the owners and operators of the named websites, as well as firms involved in the online marketing and distribution of ketamine-based products or powder formulations.
The issuance of this warning letter indicates continued CDER oversight of digital platforms marketing ketamine products directly to consumers. Regulatory teams should interpret this as a signal that the FDA is prioritizing enforcement against unauthorized online drug sellers, particularly those dealing in controlled substances or substances traditionally requiring professional supervision. The absence of specific product approvals for these platforms likely triggers misbranding and unapproved new drug violations.
Verify the regulatory status of all digital distribution channels and ensure that any controlled substance or prescription drug marketing is supported by valid NDA/ANDA approvals and distribution licenses. Legal teams should review domain portfolios for compliance with federal drug distribution requirements.
FDA Warning Letter issued to: Ket Plug / ketaminelab.org and buyketaminepowderonline.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ket-plug-ketaminelaborg-and-buyketaminepowderonlinecom-728919-06232026
Open in openFDA / FDA.gov